MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-07-2756PMID 18089786PMCID PMC3206309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

  2007cited by this paper
• Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation

  2007cited by this paper
• Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1α Activation in a Survival Response to Hypoxia*

  2007cited by this paper
• MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α

  2006cited by this paper
• MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90

  2006cited by this paper
• MUC1 oncoprotein blocks nuclear targeting of c‐Abl in the apoptotic response to DNA damage

  2006cited by this paper
• MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.

  2006cited by this paper
• Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response.

  2005cited by this paper
• Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism1

  2005cited by this paper
• MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

  2005cited by this paper
• Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.

  2005cited by this paper
• MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

  2005cited by this paper
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

  2005cited by this paper
• JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage

  2005cited by this paper
• Bcr is a negative regulator of the Wnt signalling pathway

  2005cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004influential reference
• Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.

  2004cited by this paper
• Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.

  2004cited by this paper
• Oncogenes and Tumor Suppressors (795 articles)

  2004cited by this paper
• Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.

  2003cited by this paper
• Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

  2003cited by this paper
• Minimal residual disease in chronic myeloid leukemia.

  2003influential reference
• Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T‐cell migration

  2003cited by this paper
• Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress*

  2003cited by this paper
• BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

  2002cited by this paper
• Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

  2002cited by this paper
• The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

  2002cited by this paper
• Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia

  2002cited by this paper
• The Epidermal Growth Factor Receptor Regulates Interaction of the Human DF3/MUC1 Carcinoma Antigen with c-Src and β-Catenin*

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.

  2001cited by this paper
• The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3β and β-Catenin*

  2001cited by this paper
• Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase

  2001cited by this paper
• MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets.

  2000cited by this paper
• Bcr: a negative regulator of the Bcr-Abl oncoprotein

  1999cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin

  1998cited by this paper
• Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

  1998cited by this paper
• Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase.

  1998cited by this paper
• Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents

  1995cited by this paper
• Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein.

  1995cited by this paper
• Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

  1995cited by this paper
• Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.

  1994cited by this paper
• Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.

  1994cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• The BCR gene encodes a novel serine/threonine kinase activity within a single exon.

  1991cited by this paper
• Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas.

  1989cited by this paper
• Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.

  1988cited by this paper
• Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.

  1984cited by this paper
• Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors

  1984cited by this paper
• Erythroid blast crisis in chronic myelogenous leukemia.

  1983cited by this paper
• Erythroid blast crisis in chronic myelogenous leukemia

  1983cited by this paper
• Induction of hemoglobin accumulation in human K562 cells by hemin is reversible.

  1981cited by this paper

• Mucin 4 (MUC4) Protein is Expressed in B-Acute Lymphoblastic Leukemia (B-ALL) and is restricted to BCR::ABL1 Positive and BCR::ABL-like Subtypes.

  2023cites this paper
• Integrating Clinical Cancer and PTM Proteomics Data Identifies a Mechanism of ACK1 Kinase Activation

  2023cites this paper
• AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.

  2023cites this paper
• Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway.

  2023cites this paper
• MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia

  2022cites this paper
• Identification of a Programmed Cell Death-related Signature for Prediction of Osteosarcoma

  2021cites this paper
• p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.

  2020cites this paper
• Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation

  2019cites this paper
• CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR‐ABL‐positive cells

  2018cites this paper
• Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets.

  2018cites this paper
• Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.

  2017cites this paper
• MUC1 in hematological malignancies

  2016cites this paper
• Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis

  2016cites this paper
• Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells

  2015cites this paper
• Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence

  2015cites this paper
• The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

  2015cites this paper
• Peptide-based immunotherapy in multiple myeloma

  2015cites this paper
• The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• TRICOM Poxviral-Based Vaccines for the Treatment of Cancer

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

  2014cites this paper
• Protein mislocalization: mechanisms, functions and clinical applications in cancer.

  2014cites this paper
• MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.

  2014cites this paper
• The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary

  2014cites this paper
• Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.

  2013cites this paper
• The role of mucus in the cross talk between gut bacteria and the host

  2013cites this paper
• The Post-Transcriptional Regulation of Antioxidant Enzymes

  2013cites this paper
• Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

  2013cites this paper
• Advances in immunotherapy of chronic myeloid leukemia CML.

  2013cites this paper
• MUC1c Regulates Cell Survival in Pancreatic Cancer by Preventing Lysosomal Permeabilization

  2012cites this paper
• MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism.

  2011cites this paper
• MUC 1-C oncoprotein suppresses reactive oxygen species – induced terminal differentiation of acute myelogenous leukemia cells

  2011cites this paper
• MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop

  2011cites this paper
• terminal differentiation of acute myelogenous leukemia cells induced - MUC1-C oncoprotein suppresses reactive oxygen species

  2011cites this paper
• MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.

  2011cites this paper
• Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner*

  2010cites this paper
• ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1

  2010cites this paper
• The MUC1-C oncoprotein as a target in hematologic malignancies

  2010cites this paper
• Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein

  2010cites this paper
• 14‐3‐3 Ligand Prevents Nuclear Import of c‐ABL Protein in Chronic Myeloid Leukemia

  2009cites this paper
• Mucins in cancer: function, prognosis and therapy

  2009cites this paper
• Investigating the SRC kinase HCK functions in Chronic Myelogenous Leukemia using chemical genetics methods.

  2009cites this paper
• Transcriptional control of the expression of MUC1

  2008cites this paper
• MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.

  2008cites this paper
• The Cytoplasmic Tail of MUC1: A Very Busy Place

  2008cites this paper
• Nuclear trafficking of pro-apoptotic kinases in response to DNA damage.

  2008cites this paper